onc Videos

Videos

Zev Wainberg, MD, University of California - Los Angeles

Videos

First-Line NALIRIFOX Conveys Survival Benefits for Metastatic Pancreatic Ductal Adenocarcinoma

02/07/2023

Zev Wainberg, MD, reviews results from the NAPOLI-3 study, the first study since 2010 to show an overall survival advantage in pancreatic cancer.

Zev Wainberg, MD, reviews...

02/07/2023

Oncology

Videos

Expedited FDA Approval of Teclistamab for Relapsed/Refractory Multiple Myeloma

02/05/2023

Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.

Ajai Chari, MD, provides insight...

02/05/2023

Oncology

Videos

Teclistamab Combined With Subcutaneous Daratumumab and Lenalidomide in Patients With Multiple Myeloma

02/05/2023

Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.

Emma Searle, MD, discusses...

02/05/2023

Oncology

Videos

Daratumumab Plus Lenalidomide and Dexamethasone Demonstrates Survival Benefits for Transplant-Ineligible Patients With Newly Diagnosed MM

02/05/2023

Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, discusses...

02/05/2023

Oncology

Videos

Mitapivat Improves Markers of Erythropoietic Activity in Adults With Alpha- or Beta-Non-Transfusion-Dependent Thalassemia

02/05/2023

Kevin H.M. Kuo, MD, discusses the use of mitapivat to improve erythropoiesis in patients with alpha- or beta-non-transfusion-dependent thalassemia.

Kevin H.M. Kuo, MD, discusses...

02/05/2023

Oncology

Stacey Cohen, MD, Fred Hutchinson Cancer Center

Videos

What is the Optimal Timing to Test for Circulating Tumor DNA to Detect MRD in Colorectal Cancer?

02/02/2023

Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.

Stacey Cohen, MD, reviews...

02/02/2023

Oncology

Videos

Tucatinib Plus Trastuzumab Receives FDA Approval for RAS Wild-Type, HER2-Positive Colorectal Cancer

02/02/2023

John Strickler, MD, shares insights on the FDA’s accelerated approval of tucatinib in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer.

John Strickler, MD, shares...

02/02/2023

Oncology

Aditya Bardia, MD, Massachusetts General Hospital, Boston, MA

Videos

Neoadjuvant Trastuzumab Deruxtecan for HER2-Low, HR-Positive Breast Cancer

02/02/2023

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.

At the 2022 San Antonio Breast...

02/02/2023

Oncology

Ruth O’Regan, MD, University of Rochester, NY

Videos

Breast Cancer Index Assay to Select for Ovarian Suppression in Premenopausal Women With HR-Positive Breast Cancer

01/31/2023

At the 2022 San Antonio Breast Cancer Symposium, Ruth O’Regan, MD, presented updated data from the SOFT trial, investigating the predictive potential of the breast cancer index assay in determining which premenopausal patients with...

At the 2022 San Antonio Breast...

01/31/2023

Oncology

Arielle Medford, MD, Dana-Farber Cancer Institute, Boston, MA

Videos

Monitoring for Circulating Tumors DNA to Select for Adjuvant Therapy Escalation Among Patients With HR-Positive/HER2-Negative Breast Cancer

01/30/2023

At the 2022 San Antonio Breast Cancer Symposium, Arielle Medford, MD, discusses results from the ongoing LEADER trial, investigating the efficacy of adjuvant endocrine therapy plus CDK4/6 inhibitor ribociclib for HR-positive, HER2-negative...

At the 2022 San Antonio Breast...

01/30/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology